As these effects are closely related to cognition, we believethat the results of this study have strengthened the continued evaluationof the somatostatin peptide as a therapeutic option to amelioratethe cognitive dysfunction presented in Alzheimer’s disease. This evidence concerns the gene SST and early-onset autosomal dominant Alzheimer disease.